The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The protections extend through at least 2035, with the potential for further extensions
The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The conflict is also triggering a widening public health emergency
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
The approval comes after a systematic review of published literature
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
Subscribe To Our Newsletter & Stay Updated
